WillItSurvive
Pharma and healthcare groups · Taiwan

Standard Chem & Pharm

59-year-old Taiwanese generics maker and CDMO supplier to pharma sponsors.

Defensible for now
Assessed 25 July 2026 · Evidence as of 25 July 2026
Real protection, with named pressure against it.
On the recordSince 25 July 2026 · Checkable from Q1 2026 · Every call on the record Checkpoint: Next TWSE quarterly earnings release and 2026 dividend announcement
The call

A stable, slow-growing Taiwan generics maker facing margin pressure from bigger CDMO consolidators rather than any AI-driven disruption.

Standard Chem & Pharm makes generic drugs and contract manufacturing for pharmaceuticals. It is hard to replace because it has decades of government approvals, real factories that follow strict rules, and long-standing relationships with customers. However, much larger global competitors like WuXi AppTec and Samsung Biologics are spending billions to build bigger, more efficient factories worldwide, which pushes prices down and makes smaller regional players like Standard Chem less competitive. The company's survival depends on whether it invests heavily to compete globally or stays focused on Taiwan and slowly loses its export business.

Why
01
AI pressure: None apparent. AI drug-discovery tools target new molecules, not the off-patent generics and CDMO batch work Standard Chem sells. Could AI do the core job? Unlikely.
02
Bigger players: WuXi Biologics, WuXi AppTec, Samsung Biologics, Piramal Pharma Solutions. Global CDMO giants are pouring capital into scale capacity, squeezing margins for sub-scale regional players like Standard Chem over time. Could a giant copy it? No, they are blocked.
03
What protects it. Decades of Taiwan FDA approvals, GMP plants, and entrenched distribution relationships that global rivals cannot copy quickly.
What would change this call
Standard Chem's EBITDA margin trend over next two annual reports versus current ~26.5%. Sustained decline would show CDMO consolidation is eroding pricing power.
A global CDMO acquiring or partnering with a Taiwan-based rival (e.g. ScinoPharm, Formosa Labs). Would show consolidation reaching Taiwan and directly threatening Standard Chem's contracts.
Announcement of new international CDMO client wins or capacity investment by Standard Chem. Would show the company is countering reshoring pressure rather than staying domestic-only.
Key numbers
  • TTM revenue ~NT$7.02B (~$210-225M) (2026-04-07)
  • Q2 2025 EBITDA margin ~26.5% (2025-08-05)
  • 5-year revenue CAGR +10.51% (2026-02-26)
Named risks
  • Margin compression as global CDMO consolidation ($24.86B in 2025) squeezes sub-scale regional players. Severity: high
  • No breakout growth strategy or new CDMO client wins identified in last 18 months. Severity: medium
  • Conflicting headcount and revenue figures across sources indicate weak primary-filing transparency. Severity: medium
  • Global CDMO giant could acquire a Taiwan domestic competitor and win contracts against Standard Chem. Severity: medium
  • Regulatory action such as a Taiwan FDA warning letter or lost export registration could surface. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
WuXi Biologics / WuXi AppTeccontestingPart of $24.86B global CDMO consolidation wave squeezing sub-scale regional players as of 2025-12-23
Samsung Biologicsgaining onAnnounced CDMO expansion plan at JPM Healthcare Conference on 2026-01-15, raising global capacity
YungShin Global Holding (3705.TW)contestingCited as direct Taiwan-listed generics/API peer by Yahoo Finance and FT Markets as of 2026-04-07
ScinoPharm Taiwan (1789.TW)contestingComparable domestic Taiwan API/generics peer per Yahoo Finance comparison, no date given
Piramal Pharma Solutionsgaining onPart of global CDMO scale players consolidating capacity in 2025 per pharmasource.global, 2025-12-23
Questions people ask
Is Standard Chem & Pharm profitable?
Yes. As of April 2026, Standard Chem & Pharm reported trailing twelve month revenue of about NT$7.02 billion (roughly US$210-225M) with net income of approximately NT$927.7 million, per FT Markets data dated 2026-04-07.
Who owns Standard Chem & Pharm?
It is a publicly listed, standalone company on the Taiwan Stock Exchange under ticker 1720, with no parent company found. Founder Chin Tsai Fan serves as Chairman and Tzu Ting Fan as President, indicating continued founding family control as of 2026-02-26.
Could AI replace Standard Chem & Pharm's manufacturing?
Unlikely for its core business. Generic drug manufacturing, API synthesis, and GMP quality control are physical and regulatory processes not directly displaceable by AI; only back-office documentation may see marginal AI-assisted efficiency, based on the company's 2026 evidence brief.
Is Standard Chem & Pharm laying off workers?
No layoff evidence was found. Employee counts vary by source, roughly 1,130 per FT Markets (2026-04-07) versus about 1,760 per TradingView (2025-08-05), with no dated announcement of workforce reduction located.
Who is Standard Chem & Pharm's biggest competitor?
Its closest peers are Taiwan-listed generics and API makers like YungShin Global Holding (3705.TW), ScinoPharm Taiwan (1789.TW), and SCI Pharmtech (4119.TW), per Yahoo Finance and FT Markets comparisons as of 2026-04-07, while global CDMO giants operate at a much larger scale.
Does Standard Chem & Pharm do CDMO manufacturing for other pharma companies?
Yes, the company positions itself as a Contract Manufacturing Organization and Contract Development and Manufacturing Organization offering pharmaceutical R&D and manufacturing services under international regulatory standards, per a directory listing dated 2024-11-18.
Timeline
  • 2026-04-07TTM revenue reported at NT$7.02B with net income NT$927.7M per FT Markets
  • 2026-02-26WSJ profile confirms five-year revenue growth rate of 10.51 percent through 2025-12-31
  • 2026-01-15Samsung Biologics announces CDMO expansion plan at JPM Healthcare Conference
  • 2025-12-23Global CDMO industry reshoring wave totals $24.86B in 2025 capacity investment
  • 2025-08-05Q2 2025 earnings show revenue NT$1.64B, net income NT$194.67M, EBITDA margin 26.5 percent
  • 2025-07-14Company pays 2025 dividend of NT$2.70-2.80 per share, yield about 4.3-4.7 percent
  • 2024-12-30Dun & Bradstreet reports 2024 annual revenue of $209.01 million USD
  • 1967-06-30Standard Chem & Pharm founded by Chin Tsai Fan in Tainan, Taiwan
Revision history
25 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources